November 2014

New Product - Ribomustin

Ribomustin (bendamustine hydrochloride) is an alkylating antitumour agent active against both quiescent and dividing cells. The antineoplastic and cytocidal effect of bendamustine hydrochloride is based essentially on a cross-linking of DNA single and double strands by alkylation. As a result, DNA matrix functions and DNA synthesis and repair are impaired. Ribumustin is indicated as first-line treatment of chronic lymphocytic leukaemia (Binet stage B or C); previously untreated indolent CD20-positive, stage III-IV non-Hodgkin’s lymphoma, in combination with rituximab; previously untreated CD20-positive, stage III-IV mantle cell lymphoma in combination with rituximab, in patients ineligible for autologous stem cell transplantation; and also in relapsed/ refractory indolent non-Hodgkin’s lymphoma. Ribomustin is contraindicated in severe hepatic impairment (serum bilirubin greater than 3.0 mg/dL); jaundice; severe bone marrow suppression and severe blood count alteration (leukocyte and/or platelet values dropped to < 3 x 109/L or < 75 x 109/L, respectively); major surgery less than 30 days before start of treatment; infections, especially involving leukocytopaenia; yellow fever vaccination; Ribomustin is also contraindicated during breastfeeding. Ribomustin is available as a 100 mg powder for infusion vial in packs of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629